We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Your firm has introduced or delivered for introduction into interstate commerce Blanketrol II, Norm-O-Temp, Hemotherm, and WarmAir 135 devices that have been significantly changed or modified in design and intended use without submitting a pre market notification to FDA, as required by 21 CFR 807.82(a)(3).